Third, sex-specific differences are marked for particular therapies as applied to specific cancer types, namely EGFR inhibitors in NSCLC and rituximab in NHL, beyond the underlying overall sex differences observed in these two cancer types. Here, EGFR is linked to non-Hodgkin lymphoma.